Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.
Research Interests

Papers共 328 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Combination Immunotherapy with Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary
Sapna P Patel,Rahul A Sheth, Christina Davis, Theresa Medina
Journal of clinical oncology official journal of the American Society of Clinical Oncologyno. 8 (2025): 907-911
Cited0Views0WOSBibtex
0
0
Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial
Mohamed A Gouda,Abdulrazzak Zarifa, Yali Yang,Bettzy Stephen, Serdar A Gurses, Ashabari Sprenger, Yanyan Tian,Mohamed H Derbala,Isabella Glitza Oliva,Funda Meric-Bernstam,Sapna P Patel
Journal of immunotherapy and precision oncologyno. 1 (2025): 82-88
Cited0Views0WOSBibtex
0
0
28P Decoding Biomarkers of Immune Activation in Neuroendocrine Carcinomas Treated with Ipilimumab and Nivolumab Using a Multiomic Approach
C. Haymaker, G. Kumar,Y.K. Chae, E. Gonzalez-Kozlova, C. Duault, J. Zhang,M. Othus, L. Solis Soto, G. Manyam, P. Jiang,E.R. Parra, C. Laberiano Fernandez,A. Reuben, H. Maecker, S. Gnjatic, G. Al-Atrash, J.J. Lee,S.P. Patel, R. Kurzrock
ESMO Open (2024): 102417
Cited0Views0Bibtex
0
0
Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: the Jury is Still Out
Andreas Michael Schmitt,James Larkin,Sapna P Patel
Journal of clinical oncology official journal of the American Society of Clinical Oncologypp.JCO2401572-JCO2401572, (2024)
Cited0Views0WOSBibtex
0
0
Load More
Author Statistics

#Papers: 328

#Citation: 15540

H-Index: 45

G-Index: 123

Sociability: 8

Diversity: 3

Activity: 301

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn